Arkolith/Insider Trading/AGIO/Form 4

Gheuens Sarah

Chief Medical OfficerAGIOS PHARMACEUTICALS, INC. (AGIO) · full profile →Form 4 · filed Jul 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$151K
Net Open-Market Flow
-$151K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2026Option exercise(M)8K—$089K
Jul 1, 2026Sell(S)4K$37.56$151K85K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2026Option exercise(M)8K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001439222-26-000110) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML